Global Prostate Cancer Therapeutics Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2023 –2029 |
 Market Size (Base Year) |
|
 Market Size (Forecast Year) |
|
 CAGR |
% |
| Major Markets Players |
|
>全球前列腺癌治疗市场，按药物类别（激素治疗、化疗、免疫治疗、靶向治疗）、最终用户（诊所、医院、其他）、分销渠道（医院药房、零售药房、网上销售、其他）、国家（美国、加拿大、墨西哥、巴西、阿根廷、秘鲁、南美洲其他地区、德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、匈牙利、立陶宛、奥地利、爱尔兰、挪威、波兰、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、越南、亚太其他地区、沙特阿拉伯、阿联酋、埃及、以色列、科威特、南非、中东和非洲其他地区）划分的行业趋势和预测到 2029 年
市场分析和见解全球前列腺癌治疗市场
前列腺癌治疗市场预计将在 2022-2029 年的预测期内实现市场增长。Data Bridge Market Research 分析称，在上述预测期内，市场复合年增长率将达到 8.2%，到 2029 年可能达到 219 亿美元的价值。
前列腺癌是一种前列腺内异常细胞不受控制地增殖和扩张的癌症。前列腺癌是男性第六大死亡原因，也是所有疾病导致死亡的第十一大原因。放射、化疗、激素治疗、手术和生物治疗都是治疗前列腺癌的方法。前列腺癌的治疗和控制有多种诊断和治疗方法，包括前列腺腺癌、小细胞癌、良性前列腺增生等。
前列腺癌和心血管疾病病例数的增加是导致市场增长扩大的主要驱动力。影响前列腺癌治疗市场增长率的另一个重要因素是医疗支出的增加。此外，政府资金的增加以及公共和私人组织为传播前列腺癌意识而采取的举措的增加，都是扩大前列腺癌治疗市场的因素。与筛查和诊断测试相关的技术创新以及生活方式的改变等其他因素将对前列腺癌治疗市场的增长率产生积极影响。此外，基因组学和蛋白质组学的发展以及老年人口的增长将缓冲前列腺癌治疗市场的增长率。强大药物管道的出现和新的前列腺癌治疗方法的出现是提高前列腺癌治疗市场增长率的重要因素。
Moreover, the rise in the research and development activities and innovative drugs will provide beneficial opportunities for the prostate cancer therapeutics market in the forecast period of 2022-2029. Also, high unmet needs and rise in the pharmaceutical expenditure by emerging markets will escalate the growth rate prostate cancer therapeutics market in future.
However, high cost associated with the treatment and less success rate in clinical trials for oncology drugs will impede the growth rate of prostate cancer therapeutics market. Additionally, adverse effects involved with prostate cancer therapeutics will hinder the prostate cancer therapeutics market growth. Less awareness and prolonged treatment durations will further challenge the market in the forecast period mentioned above.
This prostate cancer therapeutics market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the prostate cancer therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Prostate Cancer Therapeutics Market Scope and Market Size
The prostate cancer therapeutics market is segmented on the basis of drug class, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- Based on drug class, prostate cancer therapeutics market is segmented into hormonal therapy, chemotherapy, immunotherapy and targeted therapy. Hormonal therapy has been further sub-segmented into luteinizing hormone-releasing hormone (LHRH) antagonists, luteinizing hormone-releasing hormone (LHRH) agonists and anti-androgen. Luteinizing hormone-releasing hormone (LHRH) antagonists have been divided into zytiga and gonax. Luteinizing hormone-releasing hormone (LHRH) agonists have been divided into lupron, zoladex, eligard, decapeptyl, vantas and others. Anti-Androgen has been divided into xtandi and casodex. Chemotheraphy has been further sub-segmented into taxotere and jevtana. Immunotheraphy has been further sub-segmented as provenge. Targeted therapy has been further sub-segmented as xofigo.
- On the basis of end-users, the prostate cancer therapeutics market is segmented into clinic, hospital and others.
- 前列腺癌治疗市场也根据分销渠道细分为医院药房、零售药店、在线销售和其他。
前列腺癌治疗市场国家级分析
对前列腺癌治疗市场进行了分析，并按上述国家、药品类别、最终用户和分销渠道提供了市场规模信息。
前列腺癌治疗市场报告涉及的国家 包括美国、加拿大、墨西哥、巴西、阿根廷、秘鲁、南美洲其他地区、德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、匈牙利、立陶宛、奥地利、爱尔兰、挪威、波兰、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、越南、亚太其他地区、沙特阿拉伯、阿联酋、埃及、以色列、科威特、南非、中东和非洲其他地区。
由于北美拥有主要关键参与者、高可支配收入和发达的医疗保健基础设施，北美在前列腺癌治疗市场占据主导地位。由于患者数量不断增加、医疗保健领域投资不断增加以及政府支持不断增加，预计亚太地区将在 2022-2029 年预测期内实现增长。
报告的国家部分还提供了影响单个市场因素和国内市场法规变化，这些变化影响了市场的当前和未来趋势。新销售、替代销售、国家人口统计、疾病流行病学和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、销售渠道的影响。
患者流行病学分析
前列腺癌治疗市场还为您提供详细的市场分析，包括患者分析、预后和治疗。患病率、发病率、死亡率、依从率是报告中提供的一些数据变量。分析流行病学对市场增长的直接或间接影响，以创建更稳健、更全面的多元统计模型，用于预测增长期的市场。
竞争格局和全球前列腺癌治疗市场份额分析
前列腺癌治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、公司优势和劣势、产品发布、临床试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对前列腺癌治疗市场研究的关注有关。
前列腺癌治疗市场的一些主要参与者包括强生私人有限公司、安斯泰来制药公司、益普生制药、赛诺菲、拜耳股份公司、艾伯维公司、阿斯利康、辉瑞公司、梯瓦制药工业有限公司、雅培、武田制药有限公司、百时美施贵宝公司、葛兰素史克公司、诺华股份公司、罗氏有限公司、Myovant Sciences GmbH、Tolmar Pharmaceuticals, Inc.、Ferring BV、Dendreon Pharmaceuticals LLC. 和基因泰克公司等。
近期发展
- 2021 年 1 月，美国食品药品监督管理局 (FDA) 批准了一种名为 Relugolix 的新药，该药有望改变晚期前列腺癌的治疗方法。一项大规模临床试验发现，药物 relugolix (Orgovyx) 在降低晚期前列腺癌男性的睾酮水平方面更为成功。
- 2021 年 6 月，诺华公司宣布，美国食品药品监督管理局 (FDA) 已授予 177Lu-PSMA-617 突破性疗法认定 (BTD)，用于治疗转移性去势抵抗性前列腺癌 (mCRPC) 患者。突破性疗法认定授予正在研究用于治疗重大疾病且显示出比当前疗法有显著改善的早期临床证据的药物。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
